FLGT
Fulgent Genetics Stock Jumps 27% the Day After Q3 Results and Improved Loss Outlook
The company held its full-year revenue guidance and improved its outlook for the non-GAAP loss and cash, with revenue up about 8% year over year.
Fulgent Genetics FLGT
Fulgent Genetics, Inc. · Nasdaq · Services-Medical Laboratories
$25.70-0.31%close on Nov. 11, 2026 · volume 387K · Yahoo Finance
Price, last 57 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 2, 2026 | Hanlin Gao Chief Scientific Officer | Sold | 1,673 | $19.66 | $32,885 |
| Sept. 2, 2026 | Jian Xie President and COO | Sold | 2,127 | $19.66 | $41,809 |
| Aug. 27, 2026 | Jian Xie President and COO | Sold | 1,193 | $19.91 | $23,747 |
| Aug. 27, 2026 | Hanlin Gao Chief Scientific Officer | Sold | 939 | $19.91 | $18,691 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 18 →Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedFulgent Genetics Q3 2026 revenue of $90.4 million beats $86.3 million consensus; GAAP loss $(0.48) per share and non-GAAP loss $(0.09) both beat $(0.65) estimate; annual revenue guidance held at $330-$340 million and non-GAAP loss outlook improved